Source comparison
TB-500 Heart Health Cardioprotective Research: Study Comparison
Rodent (Temple 2019) 6 mg/kg, 2 doses over 7 days Infarct size, ejection fraction 43% vs control 27% ejection fraction improvement Demonstrated proof-of-concept for angiogenic and anti-inflammatory mechanisms Porcine (AJP 2020) 10 mg/kg, 3 doses over 14 days R
This comparison does not assign a generated winner or score.
- Rodent (Temple 2019)
- 6 mg/kg, 2 doses over 7 days
- Infarct size, ejection fraction
- 43% vs control
- 27% ejection fraction improvement
- Demonstrated proof-of-concept for angiogenic and anti-inflammatory mechanisms
- Porcine (AJP 2020)
- 10 mg/kg, 3 doses over 14 days
- Regional wall motion score
- 35% vs control
- 19% regional contractility improvement
- Confirmed dose-dependent effects in large animal model
- Human Phase I (Miami 2022)
- Escalating 0.5–2.0 mg/kg, 4 weeks
- Safety, tolerability
- Not assessed
- Established safety profile but no efficacy data
- Human case series (Europe 2024)
- 1.5 mg/kg, 5 doses over 10 days
- Ejection fraction recovery
- Not directly measured
- 15% ejection fraction improvement vs historical controls
- Suggestive but uncontrolled. Requires validation in randomized trial